Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Amortizatization of Intangibles (2020 - 2023)

Historic Amortizatization of Intangibles for Cue Biopharma (CUE) over the last 4 years, with Q3 2023 value amounting to -$12000.0.

  • Cue Biopharma's Amortizatization of Intangibles rose 8811.88% to -$12000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was -$12000.0, marking a year-over-year increase of 9779.01%. This contributed to the annual value of -$234000.0 for FY2023, which is 2710.28% up from last year.
  • Cue Biopharma's Amortizatization of Intangibles amounted to -$12000.0 in Q3 2023, which was up 8811.88% from -$73000.0 recorded in Q2 2023.
  • In the past 5 years, Cue Biopharma's Amortizatization of Intangibles registered a high of $4.1 million during Q4 2020, and its lowest value of -$220000.0 during Q4 2022.
  • In the last 4 years, Cue Biopharma's Amortizatization of Intangibles had a median value of -$12000.0 in 2023 and averaged $736458.6.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 10723.53% in 2022, then skyrocketed by 8811.88% in 2023.
  • Quarter analysis of 4 years shows Cue Biopharma's Amortizatization of Intangibles stood at $4.1 million in 2020, then decreased by 26.3% to $3.0 million in 2021, then tumbled by 107.24% to -$220000.0 in 2022, then soared by 94.55% to -$12000.0 in 2023.
  • Its Amortizatization of Intangibles stands at -$12000.0 for Q3 2023, versus -$73000.0 for Q2 2023 and -$149000.0 for Q1 2023.